Table 2:
CBF and ATT for patients with VB disease and controls separated by group and ROI
| Control (n = 20) |
Patient (n = 21) |
Between-GroupsP Value | Within-VBP Value | |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| CBF (mL/100 g/min) | ||||||
| PAR | 29.7 | 7.5 | 24.9 | 10.1 | 0.096 | 0.459 |
| OCC | 31.8 | 10.5 | 21.8 | 9.9 | 0.003a | 0.371 |
| CBF-sig (mL/100 g/min) | ||||||
| PAR | 31.3 | 6.5 | 27.9 | 8.7 | 0.161 | 0.359 |
| OCC | 32.4 | 10.1 | 22.6 | 9.6 | 0.003a | 0.307 |
| ATT (s) | ||||||
| PAR | 0.75 | 0.10 | 0.84 | 0.20 | 0.094 | 0.763 |
| OCC | 0.82 | 0.11 | 0.87 | 0.34 | 0.599 | 0.026b |
| ATT-sig (s) | ||||||
| PAR | 0.73 | 0.08 | 0.76 | 0.13 | 0.438 | 0.059 |
| OCC | 0.82 | 0.10 | 0.81 | 0.26 | 0.918 | 0.010b |
Note:—The percentage of significant voxels for CBF and ATT are shown (ie, % CBF-sig voxels and % ATT-sig voxels). ROI-adjusted CBF-sig and ATT-sig are shown, achieved by excluding voxels with a poor fit. For group comparison, a indicates a significant difference (P < .05). For within-VB analysis, b indicates a significant within-VB difference (P < .05). OCC indicates occipital cortex; PAR, parietal cortex.